Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia

Global tubeless insulin pump technology leader officially commences manufacturing of Omnipod^® 5 Automated Insulin Delivery System at new facility, enabling continued worldwide customer growth

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today hosted a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia.

Insulet President and CEO Jim Hollingshead, senior leaders, and local employees celebrate the official grand opening of the new 400,000-square-foot manufacturing facility in Johor Bahru, Malaysia. (Photo: Business Wire)

“Insulet’s remarkable growth is driven by our market-leading Omnipod 5, the first and only tubeless automated insulin delivery system in the U.S.,” said Jim Hollingshead, Insulet President and Chief Executive Officer. “Our new state-of-the-art manufacturing facility in Malaysia positions us strategically to stay ahead of the huge demand for Omnipod, ensuring our customers have uninterrupted access to our products from this thriving region with great talent.”

The new manufacturing facility will strengthen the Company’s global operational capabilities and supply chain resiliency. Located on the southern end of the Malay Peninsula just north of Singapore, the 400,000-square-foot facility is twice the size of Insulet’s highly automated manufacturing facility in Acton, Massachusetts. Currently, more than 350 full-time Insulet employees work at the new facility with plans to grow to more than 1,000 in the coming years, part of a $200M investment in the area.

The new manufacturing facility was designed with sustainable elements to eventually achieve both Green Building Index (GBI) certification and Leadership in Energy and Environmental Design (LEED) Silver certification, which is part of Insulet’s global efforts to minimize its environmental impact in the areas where it operates.

The nearly 13-acre site includes more than 5,700 solar panels that generate approximately 15% of the buildings’ power needs. To reduce potential stress to local water sources, an underground rainwater harvesting system, comprised of three rainwater capture units, was built with the capacity to satisfy 30% of the landscaping water needs. Additionally, energy efficient equipment and construction materials were used as hardscape material to reduce heat island effects.

“We congratulate Insulet on completing construction ahead of schedule,” said YB Lee Ting Han, Johor State Investment, Trade and Consumer Affairs Committee Chairman. “The manufacturing facility is up and running with a local workforce that has been upskilled and trained. This investment by Insulet will have a profound impact on the local economy for many years to come as they grow globally.”

United States Ambassador to Malaysia Edgard D. Kagan and members of the United States Embassy attended today’s ceremony.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod^® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240813627828/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation